Applications of AI in healthcare, including medical diagnostics, drug discovery, patient care solutions, and biotechnology research.
Sino Biological has launched the XPressMAX Cell Free Protein Synthesis Kit, enabling protein and antibody synthesis in three hours to support AI driven high throughput screening for antibody drug discovery.
28bio has launched CNS-3D Inflammatory Organoids, a human brain tissue model designed to test the efficacy of anti-inflammatory drugs in central nervous system diseases. The organoids combine neurons, astrocytes, and microglia to simulate inflammation and assess therapeutic responses.
Genedata has introduced Genedata Vico, an AI based platform developed with major pharmaceutical partners to accelerate Chemistry, Manufacturing, and Controls (CMC) processes and improve regulatory readiness.
Verato has announced the Verato Identity Network, a shared identity infrastructure designed to help healthcare organizations accurately identify individuals across systems and partners, enabling AI adoption and interoperability.
A large-scale study from GlycanAge and Circulate Health has confirmed IgG glycans as predictive of all-cause mortality and responsive to therapeutic plasma exchange, marking a significant advance in biological age measurement.
Azra AI has appointed oncology strategist Jessica Turgon to its Board of Directors. Turgon brings decades of experience in oncology operations and strategy, including leadership roles at Siemens Healthineers and ECG Management Consultants.
Century Health has raised $5 million in an oversubscribed seed round led by Origin Ventures to expand its AI platform CHARM, which automates the curation of clinical data with 97 percent accuracy.
Vi has released a suite of AI agents for healthcare, life sciences, and wellness enterprises, integrated across its Activate, Engage, and Operate platforms. The company also completed a $145 million transaction, valuing it at $1.64 billion.
The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) has announced eight new projects worth $9.7 million to advance biopharma manufacturing and workforce development. The projects focus on AI-based process optimization, real-time analytics, and training initiatives to strengthen the U.S. talent pipeline.
Mayo Clinic and Bayesian Health have co-developed an AI system that identifies hospitalized patients who may benefit from palliative care earlier in their stay, aiming to improve patient outcomes and reduce readmissions.
ACROBiosystems held its Innovation Day in Zurich, where experts discussed advances in biologics development and translational science. The company presented its AI platform for protein engineering, featuring examples of optimized cytokines and antibodies.
Labbit has announced the Validation Assistant, an AI capability that automates test planning, execution, and documentation for configuration updates in regulated laboratories.
Shaman has launched Shaman Atlas, a new AI powered solution that converts approved pharmaceutical promotional materials into structured, reusable data. The product will be unveiled at the Veeva Commercial and Medical Summit in Boston on May 19–20, 2026.
Enhanced has entered a strategic partnership with Rezolve Ai to integrate AI technology into its Live Enhanced digital telehealth platform, including AI medical concierge and consumer insights features.
Children's Mercy has partnered with Basepath Health to expand its cell and gene therapy capabilities, aiming to increase treatment capacity and streamline care delivery for children with rare and complex diseases.
BIOTRONIK, Charité – Universitätsmedizin Berlin, and the German Heart Center Foundation have announced a new partnership to drive research and innovation in digital and translational cardiology, focusing on AI tools and connected health technologies.
InterVenn Biosciences has appointed Alec Ford and Mitch Levine to its Board of Directors as the company advances the commercialization of its glycoproteomic diagnostics.
Sanyou Biopharmaceuticals has released AI-STAL 2.0, an upgraded version of its AI Super-Trillion Antibody Library, which integrates artificial intelligence across the full drug discovery process to enhance molecule generation, optimization, and evaluation.
Ultima Genomics has appointed Francisco De La Vega as Vice President of Germline Genomics and Distinguished Scientific Fellow. He will guide the company’s efforts in inherited genome analysis and expand applications of its sequencing technology for genetic disease research and clinical use.
OMNY Health has expanded its healthcare data ecosystem to include over 175 million de-identified patient records and launched a new oncology product suite designed to close real-world evidence gaps in cancer research.
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
